Details for New Drug Application (NDA): 211212
✉ Email this page to a colleague
The generic ingredient in SIROLIMUS is sirolimus. There is one drug master file entry for this compound. Twenty suppliers are listed for this compound. Additional details are available on the sirolimus profile page.
Pharmacology for NDA: 211212
| Mechanism of Action | Protein Kinase Inhibitors mTOR Inhibitors |
| Physiological Effect | Decreased Immunologic Activity |
Medical Subject Heading (MeSH) Categories for 211212
Suppliers and Packaging for NDA: 211212
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SIROLIMUS | sirolimus | SOLUTION;ORAL | 211212 | ANDA | Amneal Pharmaceuticals NY LLC | 69238-1594 | 69238-1594-3 | 1 CARTON in 1 KIT (69238-1594-3) / 1 BOTTLE, GLASS in 1 CARTON (69238-1594-6) / 60 mL in 1 BOTTLE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Oct 18, 2019 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
